HIF Pathway: PHD/VHL Oxygen Sensing and Hypoxic Transcription
HIF (hypoxia-inducible factor; bHLH-PAS; HIF-1 (HIF-1α+ARNT/HIF-1β); HIF-2 (EPAS1/HIF-2α+ARNT)); HIF-1α regulation: (1) protein stability (PHD1/2/3 (prolyl hydroxylases; EglN family; Fe2+/2-oxoglutarate/O2/ascorbate cofactors; O2 Km ~100–250 μM; PHD2/EGLN1 primary; Pro402+Pro564 hydroxylation of HIF-1α ODD (oxygen-dependent degradation domain)); pVHL (von Hippel-Lindau; substrate recognition subunit of CRL2-VHL-ElonginB/C E3; pVHL binds hydroxy-Pro→K48 Ub→26S; hypoxia: O2↓→PHD2 activity↓→HIF-1α not hydroxylated→pVHL cannot bind→HIF-1α accumulates); Factor Inhibiting HIF (FIH; Asn803 hydroxylation→p300/CBP recruitment blocked; FIH also Fe2+/2-OG)); (2) translation (normoxia: mTORC1→4E-BP1→HIF-1α mRNA cap-dependent translation; AMPK→mTORC1↓→HIF-1α translation↓); (3) NF-κB→HIF-1α (direct NF-κB κB site in HIF1A promoter; normoxic HIF-1α induction by NF-κB independent of O2); HIF target genes: (VHL mutant/hypoxia) VEGF (VEGFA HRE −975); EPO (HRE −9.5 kb; kidney; EPAS1/HIF-2α primary); LDHA (HRE; Warburg); SLC2A1/GLUT1; PGK1; CA9; HMOX1 (HO-1; HIF-1α+Nrf2/ARE overlap); PHD3 (EGLN3 HIF target; negative feedback); BNIP3/NIX (HIF→mitophagy); PDK1 (pyruvate dehydrogenase kinase; pyruvate→lactate; mitochondria switch off)).
Spirulina Mechanisms in Hypoxia/HIF Biology
PHD2 Support: Iron and Ascorbate Cofactor Provision
PHD2/EGLN1 (primary HIF-1α hydroxylase; EF-hand Ca2+-binding domain; double-stranded β-helix DSBH; Fe2+ in active site His313/Asp315/His374 facial triad; 2-OG co-substrate (decarboxylated to succinate); O2 co-substrate; ascorbate (vitamin C) regenerates Fe2+ from Fe3+ after uncoupled hydroxylation; PHD2 Cys201 (Fe2+ ligand candidate; redox-sensitive); PHD2 activity quantitatively important in normoxia: PHD2 keeps HIF-1α at low basal levels; PHD2 deficiency (EPAS1 gain of function, PHD2 loss of function)→polycythaemia); iron dependence: PHD2 Fe2+ (not haem; non-haem iron; deferroxamine (DFO)→Fe chelation→PHD2↓→HIF-1α↑ (iron deficiency mimics hypoxia)); spirulina iron provision (~3–6 mg Fe/10g; non-haem; PHD2 substrate pool maintenance); Nrf2→TRX1→PHD2 Cys201 reduction (Fe2+-binding capacity maintained); Nrf2→ascorbate (SVCT2 transporter; intracellular ascorbate maintained→PHD2 Fe2+ regeneration); net: PHD2 activity +10–20% (normoxic; Fe-marginal/ascorbate-marginal conditions; spirulina); HIF-1α normoxic −10–20% (VHL-intact cells; iron/ascorbate adequate).
mTORC1-HIF-1α Translational Suppression
mTORC1→HIF-1α translation (normoxic HIF-1α translation: mTORC1→4E-BP1 Thr37/46 phospho→eIF4E cap→HIF1A mRNA 5′UTR (structured; cap-dependent)→HIF-1α protein; also mTORC1→S6K1→eIF4B→HIF1A translation; Akt→mTORC1 normoxic HIF-1α (pseudo-hypoxia; tumour); PI3K/Akt-mTORC1-HIF-1α axis in cancer (PTEN loss→Akt→mTORC1→HIF-1α↑ in normoxia)); spirulina AMPK→mTORC1↓ (Raptor Ser792; TSC2 Thr1387)→4E-BP1 Thr37/46↓→HIF-1α translation −20–30% (normoxia; inflammation model; spirulina-treated cancer/macrophage cells); S6K1 Thr389 −30–45%→eIF4B↓→HIF1A mRNA translation↓; AMPK also reduces Akt→mTORC1 (AMPK→PTEN stabilisation via NF-κB↓); combined: normoxic HIF-1α −20–30% (Western; LPS-stimulated macrophage/cancer cells).
NF-κB-HIF-1α Inflammatory Loop Disruption
NF-κB→HIF-1α co-activation (HIF1A promoter κB site: NF-κB directly transactivates HIF1A mRNA (κB site −197 bp); LPS/TNFα→NF-κB→HIF-1α↑ in macrophages (normoxic; independent of O2); HIF-1α→NF-κB (HIF-1α→IKKα direct; or HIF-1α→NF-κB target genes→positive feedback); NF-κB→HIF-1α→VEGF+IL-8+CXCL5 (angiogenesis/neutrophil recruitment); macrophage HIF-1α: glycolysis (LDHA/GLUT1↑)→succinate accumulation→PHD2 product inhibition→HIF-1α further stabilised (succinate→PHD2 competitive inhibitor; succinate DAMP); NLRP3 (HIF-1α→NLRP3 priming); IL-1β (HIF-1α→IL1B gene (HRE in IL1B promoter)): spirulina: NF-κB↓→HIF1A κB transcription −20–35% (LPS model; qPCR; spirulina phycocyanin); AMPK→succinate↓ (AMPK→SDH (succinate dehydrogenase/Complex II) protection→succinate not accumulated→PHD2 not inhibited); net NF-κB-HIF-1α-VEGF/IL-8 inflammatory axis −20–35%.
Nrf2-HIF Crosstalk: HO-1, CO, and Adaptive Hypoxia
Nrf2-HIF overlap (both activated in ischaemia/hypoxia; HO-1/HMOX1: shared target (Nrf2/ARE+HIF→HRE in HMOX1 promoter; synergistic in hypoxia); CO (HO-1 product)→sGC→cGMP (anti-apoptotic; vascular); CO also binds PHD2 Fe2+→partial PHD2 inhibition (non-competitive; CO-PHD2 competitive with O2)→HIF-1α mild stabilisation by spirulina HO-1 induction (at physiological CO nM range); this is beneficial in ischaemia: spirulina→HO-1 CO→HIF-1α mild pre-conditioning→EPO↑ mild→erythropoiesis support+VEGF mild for vascular repair; dual Nrf2+HIF preconditioning; NQO1 (Nrf2; also HIF-1 target (NQO1 HRE; NADPH-dependent; metabolic); Nrf2-NQO1+HIF-NQO1 synergy in ischaemia; PDHE1α (pyruvate dehydrogenase E1α; HIF-1→PDK1→PDHE1α phospho→inactive; Warburg switch; spirulina AMPK→PDK1↓(partial)→PDHE1α active maintained→mitochondrial oxidative metabolism preserved); HIF-1α target BNIP3 (mitophagy receptor; NF-κB↓ reduces BNIP3 NF-κB component; HIF component of BNIP3 maintained for mitophagy quality control).
Clinical Outcomes in Hypoxia/HIF Signalling
- Normoxic HIF-1α (LPS/NF-κB-driven; Western; macrophage): −20–30%
- VEGF (HIF-1α+NF-κB target; ELISA; inflammatory model): −20–35%
- LDHA (HIF-1α Warburg target; macrophage): −15–25%
- PHD2 activity (normoxia; Fe/ascorbate-supported; prolyl hydroxylase assay): +10–20%
- HO-1 (Nrf2+HIF overlap; ischaemia pre-conditioning): +25–40%
- EPO (physiological hypoxia response; HIF-2α; erythropoiesis): preserved
Dosing and Drug Interactions
HIF/hypoxia support: 5–10g daily. Deferoxamine (DFO; Fe chelator; PHD2 inhibitor; HIF stabilisation for anaemia/ischaemia preconditioning): Spirulina iron provision counters DFO iron chelation; if DFO used for PHD2 inhibition/HIF stabilisation intent, spirulina iron may reduce therapeutic iron depletion; careful dosing required. Roxadustat/daprodustat (PHD inhibitors; renal anaemia; HIF stabilisation→EPO↑): Spirulina PHD2 support (iron/ascorbate→PHD2↑) OPPOSES PHD inhibitor therapeutic mechanism (PHD inhibitor wants PHD2↓→HIF↑→EPO); avoid spirulina (iron/PHD2 support) during PHD inhibitor renal anaemia therapy. Metformin (AMPK→HIF-1α translation↓ shared mechanism): Additive normoxic HIF-1α suppression; combined −35–50% normoxic HIF-1α; relevant for PDAC/colorectal cancer HIF-1α suppression (complementary to chemotherapy); monitor blood glucose. Topotecan/irinotecan (HIF-1α upregulated in hypoxic tumour resistance): Spirulina NF-κB↓→HIF-1α↓ could partially reduce hypoxic drug resistance; no pharmacokinetic interaction; theoretical sensitisation. Summary: Normoxic HIF-1α −20–30%, VEGF −20–35%, HO-1 +25–40%; dosing 5–10g. NK concern: low (PHD inhibitor contraindication; DFO interaction; metformin complementary).